Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients-Reference-Cited by-同舟云学术

Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

Published:2019-03-08 Issue:9 Volume:60 Page:1259-1265
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Aalbersberg Else A.,Huizing Daphne M.V.,Walraven Iris,de Wit-van der Veen Berlinda J.,Kulkarni Harshad R.,Singh Aviral,Stokkel Marcel P.M.,Baum Richard P.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference39 articles.

1. Current knowledge on diagnosis and staging of neuroendocrine tumors;Oberg;Cancer Metastasis Rev.,2011

2. Nothing but NET: a review of neuroendocrine tumors and carcinomas;Oronsky;Neoplasia.,2017

3. Radionuclide therapy for neuroendocrine tumors;Cives;Curr Oncol Rep.,2017

4. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide: a case history;Krenning;Ann N Y Acad Sci.,1994

5. PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors;Cancers;2024-08-28

2. Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT;EJNMMI Reports;2024-08-08

3. Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients;Journal of Neuroendocrinology;2024-03-13

4. Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience;Frontiers in Endocrinology;2024-01-04

5. Enhancing precision: A predictive model for ¹⁷⁷Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative ⁶⁸Ga-DOTATATE PET and clinicopathological biomarkers;Theranostics;2024